Ser376

Site Information
GVEDTEWsNtQtEEA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 15416617

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 , 6 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:	HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , liver cancer ( 1 ) , hepatocellular carcinoma ( 1 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 )
Relevant cell line - cell type - tissue:	breast ( 2 ) , HeLa (cervical) ( 6 ) , Huh7 (hepatic) ( 1 ) , Jurkat (T lymphocyte) ( 3 ) , K562 (erythroid) ( 4 ) , lung ( 5 )

Upstream Regulation
Kinases, in vitro:	VRK1 (human) ( 1 )
Treatments:	low_glucose ( 1 ) , UV ( 1 )

References
1	Yokobori K, Miyauchi Y, Williams JG, Negishi M (2020) Phosphorylation of vaccinia-related kinase 1 at threonine 386 transduces glucose stress signal in human liver cells. Biosci Rep 40 32266931 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
4	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
5	Rikova K (2010) CST Curation Set: 9468; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
6	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info